The Clinical Impact of Solid and Micropapillary Patterns in Resected Lung Adenocarcinoma  Naoki Yanagawa, MD, PhD, Satoshi Shiono, MD, PhD, Masami Abiko,

Slides:



Advertisements
Similar presentations
The Correlation of the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS)
Advertisements

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.
Impact of Solid Minor Histologic Subtype in Postsurgical Prognosis of Stage I Lung Adenocarcinoma  Tianxiang Chen, MD, PhD, Jizhuang Luo, MD, Haiyong.
Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.
APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26
Results of Surgical Treatment for Patients with Small Cell Lung Cancer
Clinicopathological and Survival Analysis of Japanese Patients with Resected Non- Small-Cell Lung Cancer Harboring NKX2-1, SETDB1, MET, HER2, SOX2, FGFR1,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Use of Oncogenic Driver Mutations in Staging of Multiple Primary Lung Carcinomas: A Single-Center Experience  Ramsey Asmar, MD, Joshua R. Sonett, MD,
Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base  Amy C. Moreno,
IA05.01 Lung Cancer Cases Journal of Thoracic Oncology
Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD-1/PD-L1.
Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients  Hes A.P. Brokx, MD, Otto Visser, MD, PhD,
Role of CT and PET Imaging in Predicting Tumor Recurrence and Survival in Patients with Lung Adenocarcinoma  Ho Yun Lee, MD, PhD, So Won Lee, MD, Kyung.
Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma  Lih-Chyun Chang, MD, Kuan-Yu Chen, MD, PhD, Jin-Yuan.
Prognostic Factors in Completely Resected Node-Negative Lung Adenocarcinoma of 3 cm or Smaller  Jung-Jyh Hung, MD, PhD, Yi-Chen Yeh, MD, Yu-Chung Wu,
Tumor Spread through Air Spaces is an Important Pattern of Invasion and Impacts the Frequency and Location of Recurrences after Limited Resection for.
Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD 
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
Postoperative Prognosis in Patients with Non-small Cell Lung Cancer According to the Method of Initial Detection  Takeshi Hanagiri, MD, PhD, Kenji Sugio,
Sleeve lung resection for lung cancer: Analysis according to the type of procedure  Kazumichi Yamamoto, MD, Yoshihiro Miyamoto, MD, Akihiro Ohsumi, MD,
Imaging Phenotyping Using Radiomics to Predict Micropapillary Pattern within Lung Adenocarcinoma  So Hee Song, MD, Hyunjin Park, PhD, Geewon Lee, MD,
Tumor histology predicts mediastinal nodal status and may be used to guide limited lymphadenectomy in patients with clinical stage I non–small cell lung.
Why Do Pathological Stage IA Lung Adenocarcinomas Vary from Prognosis
A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib  Parneet K. Cheema, MD, MBiotech, FRCPC  Journal.
Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.
Lung Cancer and Prognosis in Taiwan: A Population-Based Cancer Registry  Bing-Yen Wang, MD, Jing-Yang Huang, Ching-Yuan Cheng, MD, Ching-Hsiung Lin, MD,
Impact of Lepidic Component Occupancy on Effects of Adjuvant Chemotherapy for Lung Adenocarcinoma  Shinsuke Sasada, MD, PhD, Yoshihiro Miyata, MD, PhD,
Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer  Masahiko Harada,
Clinical Characteristics and Outcomes for Patients With Thymic Carcinoma: Evaluation of Masaoka Staging  Anya M. Litvak, MD, Kaitlin Woo, MS, Sara Hayes,
Jeffrey Bradley, MD, Issam El Naqa, PhD  Journal of Thoracic Oncology 
Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors  Benny Weksler, MD, Anthony Holden, MD, Jennifer.
Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database  Laura C. Caprario, MD, MS,
Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review  Arianna Casagrande, MD, Federica Pederiva,
Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green 
The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition  Sai-Hong.
Clinical Outcomes and Prognosis of Recurrent Thymoma Management
New IASLC/ATS/ERS Classification and Invasive Tumor Size are Predictive of Disease Recurrence in Stage I Lung Adenocarcinoma  Naoki Yanagawa, MD, PhD,
PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered?  Steven G. Gray, PhD  Journal of Thoracic.
Role of CT and PET Imaging in Predicting Tumor Recurrence and Survival in Patients with Lung Adenocarcinoma  Ho Yun Lee, MD, PhD, So Won Lee, MD, Kyung.
Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q
Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.
Tumor Spread through Air Spaces Affects the Recurrence and Overall Survival in Patients with Lung Adenocarcinoma >2 to 3 cm  Chenyang Dai, MD, Huikang.
Survival Differences by Gender for Resected Non-small Cell Lung Cancer: A Retrospective Analysis of 12,509 Cases in a Japanese Lung Cancer Registry Study 
Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed  Emanuela Taioli, MD, PhD, Raja Flores, MD 
The Role of Extent of Surgical Resection and Lymph Node Assessment for Clinical Stage I Pulmonary Lepidic Adenocarcinoma: An Analysis of 1991 Patients 
Validation of the IASLC/ATS/ERS Lung Adenocarcinoma Classification for Prognosis and Association with EGFR and KRAS Gene Mutations: Analysis of 440 Japanese.
EGFR Mutation and Brain Metastasis in Pulmonary Adenocarcinomas
Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease  Hao-Xian Yang,
The Prognostic Impact of Cigarette Smoking on Patients with Non-small Cell Lung Cancer  Ryo Maeda, MD, Junji Yoshida, MD, PhD, Genichiro Ishii, MD, PhD,
Clinical Relevance of Our Multimodality Prognostic Score
It’s All in the “Swerve of the Curve”
Adjuvant Surgery after Carboplatin and VP16 in Resectable Small Cell Lung Cancer  Giulia Veronesi, MD, Paolo Scanagatta, MD, Francesco Leo, MD, Tommaso.
The Port Site Recurrence after a Thoracoscopic and Video-Assisted Esophagectomy for Advanced Esophageal Cancer  Satoshi Yamamoto, PhD, Katsunobu Kawahara,
Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases  Kanji Nagai, MD, Yasunori Sohara, MD, Ryosuke Tsuchiya, MD,
Pulmonary Resection for Metastases from Colorectal Cancer
Significance of Smoking as a Postoperative Prognostic Factor in Patients with Non- small Cell Lung Cancer  Takeshi Hanagiri, MD, PhD, Kenji Sugio, MD,
Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: The Japan Clinical.
Outcome of Multimodality Treatment for 188 Cases of Type B3 Thymoma
Combined Evaluation of Postoperative Serum Levels of Carcinoembryonic Antigen Less than or Equal to 2.5 ng/ml and Absence of Vascular Invasion may Predict.
Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.
Influence of Ground Glass Opacity and the Corresponding Pathological Findings on Survival in Patients with Clinical Stage I Non–Small Cell Lung Cancer 
P New Clinical T Classification Is Associated with Pathological Stage I Invasive Adenocarcinoma with Solid Histologic Subtype  Y. Sawai, J. Nitadori,
APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28
Disease-Free Interval Length Correlates to Prognosis of Patients Who Underwent Metastasectomy for Esophageal Lung Metastases  Satoshi Shiono, MD, Masafumi.
Prognostic Role of Subtype Classification in Small-Sized Pathologic N0 Invasive Lung Adenocarcinoma  Tomoharu Yoshiya, MD, Takahiro Mimae, MD, PhD, Yasuhiro.
Razvan Diaconescu, MD, Chantal Lafond, MD, Renaud Whittom, MD 
Robert Comis, MD, The Passing of a “Lung Man”
Reply to “Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer: Methodological Issues”  Boris Sepesi,
Presentation transcript:

The Clinical Impact of Solid and Micropapillary Patterns in Resected Lung Adenocarcinoma  Naoki Yanagawa, MD, PhD, Satoshi Shiono, MD, PhD, Masami Abiko, MD, PhD, Masato Katahira, MD, Mitsumasa Osakabe, MD, PhD, Shin-ya Ogata, MD, PhD  Journal of Thoracic Oncology  Volume 11, Issue 11, Pages 1976-1983 (November 2016) DOI: 10.1016/j.jtho.2016.06.014 Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 The recurrence-free survival curve (A) and the overall survival curve (B) according to the predominant histopathological patterns in all stages (N = 531). The recurrence-free survival and overall survival differed significantly among the predominant histopathological patterns (p < 0.01 and p < 0.01, respectively). Lepidic means lepidic adenocarcinoma with adenocarcinoma in situ and minimally invasive adenocarcinoma. IMA, invasive mucinous adenocarcinoma. Journal of Thoracic Oncology 2016 11, 1976-1983DOI: (10.1016/j.jtho.2016.06.014) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 The recurrence-free survival curve (A) and the overall survival curve (B) according to the five subgroups in all stages (N = 531). The recurrence-free survival and overall survival differed significantly among the five subgroups (p < 0.01 and p < 0.01, respectively). S–, solid pattern absent; MP –, micropapillary pattern absent; S+ not pre, solid pattern present but not predominant; MP+ not pre, micropapillary pattern present but not predominant; S pre, solid predominant pattern; MP pre, micropapillary predominant pattern. Journal of Thoracic Oncology 2016 11, 1976-1983DOI: (10.1016/j.jtho.2016.06.014) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 3 The recurrence-free survival curve (A) and the overall survival curve (B) according to the five subgroups in patients with stage I disease (N = 420). The recurrence-free survival and overall survival differed significantly among the five subgroups (p < 0.01 and p < 0.01, respectively). S–, solid pattern absent; MP –, micropapillary pattern absent; S+ not pre, solid pattern present but not predominant; MP+ not pre, micropapillary pattern present but not predominant; S pre, solid predominant pattern; MP pre, micropapillary predominant pattern. Journal of Thoracic Oncology 2016 11, 1976-1983DOI: (10.1016/j.jtho.2016.06.014) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions